Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 6/20 | 0.46 |
| ▸ | PDE4A | P27815 | 12/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4196594 | 0.90 | PDE4B (0.49) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4193004 | 0.82 | PDE4A (0.52) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4202645 | 0.82 | PDE4A (0.51) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4200733 | 0.82 | PDE4B (0.44) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3131424 | 0.82 | PDE4B (0.43) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1157603 | 0.82 | PDE4B (0.46) | PDE4BPDE4APDE4CPDE4DGAA | |
| SCHEMBL1157744 | 0.81 | PDE4B (0.47) | PDE4BPDE4APDE4CPDE4DGAA | |
| SCHEMBL3204715 | 0.80 | PDE4B (0.40) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4200609 | 0.79 | PDE4B (0.40) | PDE4BPDE4APDE4CPDE4DGAA | |
| SCHEMBL3205698 | 0.79 | PDE4B (0.44) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | SCHUMACHER RICHARD A | 2009-02-19 | — | — | US | disclosed |
| US-7405230-B2 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-07-29 | — | — | US | disclosed |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | MEMORY PHARMACEUTICALS CORP. (US) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048255-A1 | PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED ANILINE AND DIPHENYLAMINE ANALOGS | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4A 1/4885PDE4C 7/4885 |
| US-20050119225-A1 | Phosphodiesterase 4 inhibitors, including N-substituted aniline and diphenylamine analogs | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE4A 1/4885PDE4C 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.